Merck KGaA Finds The Right Home For Disease-Modifying OA Agent In Novartis
Licenses Nanobody M6495 To Swiss Firm
Novartis has added an anti-osteoarthritic Nanobody, M6495, to its growing pipeline of candidates for the condition, in a €450m agreement with Merck KGaA that sees the latter deliver on its plans to find new homes for its osteoarthritis pipeline.
